Loading...
Market
Story
Pfizer's Gene Therapy for Duchenne Muscular Dystrophy Fails in Phase 3 Trial on June 12, Showing No Improvement
Jun 12, 2024, 09:15 PM
Pfizer's phase 3 study of its investigational gene therapy for Duchenne muscular dystrophy (DMD) failed to meet its primary endpoint, showing no significant improvement in motor function among ambulatory boys aged 4-7 compared to placebo. The trial also did not show significant differences in key secondary endpoints. This marks the second large, randomized, placebo-controlled trial of a Duchenne gene therapy to fail in achieving its primary goal. On June 12, Pfizer confirmed the failure of the trial, which targeted a muscle-wasting disorder.
View original story
Similar markets
Success • 33%
Partial Success • 33%
Failure • 33%
Pfizer • 25%
Sarepta Therapeutics • 25%
Solid Biosciences • 25%
Other • 25%
Seek further regulatory approvals • 33%
Begin commercial production • 33%
Partner with another company for distribution • 34%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Novartis • 25%
10-20 • 33%
21-30 • 33%
31+ • 34%
